Log In
Print this Print this

ALKS 5461

  Manage Alerts
Collapse Summary General Information
Company Alkermes plc
DescriptionCombination of ALKS 33, a mu opioid receptor (OPRM1; MOR) antagonist, and buprenorphine
Molecular Target Mu opioid receptor (MOR) (OPRM1) ; Kappa opioid receptor (KOR) (OPRK1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationDepression
Indication DetailsTreat major depressive disorder (MDD); Treat refractory major depressive disorder (MDD)
Regulatory Designation

U.S. - Fast Track (Treat refractory major depressive disorder (MDD))


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today